You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀-B(01952.HK):將獲得候選產品SPR206在大中華等地域的相關專利權益
格隆匯 01-18 17:20

格隆匯 1 月 18日丨雲頂新耀-B(01952.HK)公佈,公司與Spero Therapeutics公司達成了一項授權合約的修訂,根據該協定的修訂內容,公司將獲得候選產品SPR206在大中華區、韓國和部分東南亞國家("區域")的相關專利權益。2019年1月,兩家公司曾宣佈一項合作協定,在上述區域對SPR206進行開發、製造和商業化。SPR206是一款針對多重耐藥("MDR")革蘭氏陰性菌感染的創新治療選擇,目前仍在臨牀開發階段。Spero公司此前發表了SPR2061期雙盲、安慰劑對照的單次給藥劑量遞增(SAD)和多次給藥劑量遞增(MAD)臨牀試驗資料,資料顯示在針對目標多重耐藥革蘭氏陰性菌感染的治療範圍劑量內,SPR206耐受性良好。此外,在該研究中未觀察到腎毒性的證據。Spero公司計劃在2021年啟動更多的1期研究,以評估SPR206進入肺間隔的滲透性和在腎功能不全患者中的藥代動力學。

據悉,SPR206是一種潛在的同類領先的新型多黏菌素類抗生素,旨在減少目前臨牀上多黏菌素B和粘菌素治療時產生的腎臟毒性。多黏菌素常被用作對抗多重耐藥革蘭氏陰性菌感染的最後手段,但它們在臨牀使用時與明顯的神經毒性和腎毒性有關。公司的合作伙伴Spero Therapeutics公司在健康志願者中進行的雙盲、安慰劑對照1期臨牀試驗中,在針對目標多重耐藥革蘭氏陰性細菌感染的可能治療範圍內,SPR206表現出良好的耐受性,更重要的是,在研究的劑量範圍內也沒有顯示腎毒性的證據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account